SRPT Earnings

SRPT reported its earnings on 2026-05-06, showcasing a revenue of 730.80M against an estimate of 467.85M, resulting in a 56.2% surprise. The EPS was 3.09, surpassing the expected 0.39 by 692.31%. The stock experienced a -9.68% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following SRPT's earnings announcement on 2026-05-06, the stock price moved by -9.68% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, SRPT's stock price tends to shift by an average of 2.94% in the 10 days leading up to earnings and -2.84% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate SRPT's annual revenue to reach 379.61M, while the EPS is projected at 0.54. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between SRPT's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, SRPT's stock price typically moves by 2.94% in the 10 days before its earnings and -2.84% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 0.54 and revenue of 379.61M.

The earnings call summary highlights a 20% YoY revenue growth and a shift from a net loss to a $50 million net income, indicating strong financial performance. The increase in R&D expenses supports future growth, while improved cash flow reflects efficient management. Despite the lack of strategic and operational updates, the financial results and positive market demand for new therapies suggest a strong positive sentiment. The absence of negative feedback in the Q&A further supports this outlook.